GlassScriptPhysician profile
Morris M Ahdoot
NPI 1992748420
$6,710.59
in general payments reported to CMS, 2019-2025
28 companies · $466 in 2025
The $466 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,792 · 2020: $372 · 2021: $1,126 · 2022: $668 · 2023: $991 · 2024: $296 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,661 · Education: $92.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.58 |
| Education | $92.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,757.27 | 2019-2025 | Lo Loestrin Fe, Botox |
| Ethicon INC. | $942.20 | 2019 | |
| Merz North America, INC. | $882.75 | 2019-2023 | Xeomin |
| Intuitive Surgical, INC. | $635.44 | 2019-2021 | |
| Allergan, INC. | $295.44 | 2019-2022 | |
| Exeltis, USA INC. | $292.76 | 2019-2025 | Slynd |
| Pfizer INC. | $269.48 | 2021-2024 | |
| Daiichi Sankyo INC. | $230.74 | 2021-2022 | |
| Aspira Women'S Health INC | $169.25 | 2021-2023 | Ova1 |
| Evofem Biosciences, INC. | $164.34 | 2022-2025 | Phexxi, Solosec, Phexx |
| Duchesnay USA Incorporated | $122.95 | 2019 | |
| Hologic Sales and Service, LLC | $121.85 | 2020-2025 | Fetal Fibronectin Enzyme Immunoassay |
| Mayne Pharma Commercial LLC | $121.76 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $117.29 | 2023-2024 | Myfembree |
| Galderma Laboratories, L.P. | $109.84 | 2021-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $106.40 | 2023 | Myrbetriq |
| Biogen, INC. | $82.20 | 2025 | Zurzuvae |
| Vertical Pharmaceuticals, LLC | $48.00 | 2019 | |
| Therapeuticsmd, INC. | $40.61 | 2019-2021 | |
| Csl Behring | $32.80 | 2024 | Haegarda |
| Organon LLC | $26.81 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $26.41 | 2024 | |
| Merck Sharp & Dohme LLC | $24.77 | 2025 | Gardasil 9 |
| Myovant Sciences INC. | $24.61 | 2022 | |
| Amag Pharmaceuticals, INC. | $22.16 | 2019 | |
| Coopersurgical, INC. | $17.39 | 2019 | |
| Meditrina | $13.58 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Ahdoot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.